In this week's episode: key themes for JPM; 2024 launches a breakout for liver disease; obesity drug readouts this year; IgA nephropathy snapshot; and only half of 2024 launches were from big pharma.
In this week's episode: Pfizer’s 2025 policy outlook; made in China blockbusters elusive; Vertex’s pain plans; Q3’s top 10 drugs; and sickle cell disease at ASH.
In this week's episode: a snapshot of the atopic dermatitis market; Bill Burns profile; GSK’s Blenrep makes a comeback; CML results at ASH; and what’s driving optimism on India.
In this week's episode: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug.
In this week's episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India.
The second podcast in our series marking 20 years of the Scrip Awards and their recognition of biopharma innovation looking back at some of the trends that have shaped the sector in that time.
In this week's episode: Novo’s semaglutide looks good in NASH; J&J’s psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024.
